These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 4725203)

  • 1. Tempering power with responsibility.
    Feldmann EG
    J Pharm Sci; 1973 Aug; 62(8):I. PubMed ID: 4725203
    [No Abstract]   [Full Text] [Related]  

  • 2. Personal responsibility and the Food and Drug Law.
    Janssen WF
    FDA Consum; 1975 Nov; 9(9):10-3. PubMed ID: 10308122
    [No Abstract]   [Full Text] [Related]  

  • 3. Knowledge is power: legislative control of drug industry trade secrets.
    O'Reilly JT
    Spec Law Dig Health Care (Mon); 1987 May; 8(15):7-31. PubMed ID: 10281981
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of consultants in the parenteral industry.
    Agalloco JP
    J Parenter Sci Technol; 1986; 40(6):277-83. PubMed ID: 3819981
    [No Abstract]   [Full Text] [Related]  

  • 5. The parenteral drug industry: recent findings.
    Fry EM
    J Parenter Sci Technol; 1982; 36(2):55-8. PubMed ID: 7077464
    [No Abstract]   [Full Text] [Related]  

  • 6. The drug industry and drug effectiveness.
    Curran WJ
    N Engl J Med; 1970 Aug; 283(6):304-5. PubMed ID: 5427059
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug industry trying to change FDA's slow but sure policy.
    Demkovich LE
    Natl J (Wash); 1979 Jul; 11(29):1211-5. PubMed ID: 10242491
    [No Abstract]   [Full Text] [Related]  

  • 8. A strike against preemption.
    Nat Biotechnol; 2009 May; 27(5):397. PubMed ID: 19430422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical costs and the drug industry.
    Schwartz H
    Wall St J Midwest Ed; 1980 Apr; 60(132):22. PubMed ID: 10245744
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial: Some caveats for the FDA.
    Calif Med; 1973 Oct; 119(4):64-5. PubMed ID: 4749314
    [No Abstract]   [Full Text] [Related]  

  • 11. View from the Nation's Capital.
    Romansky MA
    J Clin Psychopharmacol; 1984 Jun; 4(3):161-2. PubMed ID: 6096408
    [No Abstract]   [Full Text] [Related]  

  • 12. When does compounding become manufacturing?
    Gushee J
    J Am Vet Med Assoc; 1994 Jul; 205(2):235-6. PubMed ID: 7928585
    [No Abstract]   [Full Text] [Related]  

  • 13. Dietary supplements: background for dialogue between the industry and the medical profession.
    Friede AI
    Food Drug Law J; 1998; 53(3):413-20. PubMed ID: 10346719
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug research and social profit.
    Markoe F
    Med Mark Media; 1978 Sep; 13(9):10, 12, 14 passim. PubMed ID: 10238519
    [No Abstract]   [Full Text] [Related]  

  • 15. Parenteral manufacturing and legal regulations.
    Tamura LK
    Bull Parenter Drug Assoc; 1968; 22(6):261-6. PubMed ID: 5727161
    [No Abstract]   [Full Text] [Related]  

  • 16. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

  • 17. Another round over generics.
    Kosterlitz J
    Natl J (Wash); 1985 Oct; 17(42):2373, 2376. PubMed ID: 10274030
    [No Abstract]   [Full Text] [Related]  

  • 18. Plugs for drugs.
    Masson A; Rubin PH
    Regulation; 1986; 10(1):37-43, 53. PubMed ID: 10280556
    [No Abstract]   [Full Text] [Related]  

  • 19. Under attack.
    Mod Vet Pract; 1981 Feb; 62(2):97-101. PubMed ID: 7254190
    [No Abstract]   [Full Text] [Related]  

  • 20. New law broadens FDA safety authority, renews user fees.
    Fox JL
    Nat Biotechnol; 2007 Nov; 25(11):1189-90. PubMed ID: 17989653
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.